Conclusion and future directions Recent studies provide potent evidence for the pleiotropic effects of GLP-1 on the cardiovascular system
In addition to weight loss, GLP-1 agonists enhance cardiometabolic risk factors by decreasing visceral fat, blood pressure, and inflammation [38]
Research published in Frontiers in Nutrition in 2025 found that people using GLP-1 medications often consume lower amounts of key nutrients, including vitamin D, calcium, and magnesium, which may affect energy levels and muscle health
Stratified by the level of weight reduction To explore the relationship between significant weight loss during treatment and long-term weight loss maintenance, we performed subgroup analyses of whether significant weight loss was associated with weight regain
Coverage for the weight loss drugs presents a dilemma for the Trump administration, which has identified as priorities attacking chronic health conditions and reducing federal spending